OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	151
Thalassaemia in China	110
Radiation and leukaemia: Which leukaemias and what doses?	108
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	106
Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies	97
Editorial Board	86
Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia	77
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	64
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy	60
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	56
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	52
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	50
Editorial Board	49
Host-directed therapies modulating innate immunity against infection in hematologic malignancies	47
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review	44
TP53 in AML and MDS: The new (old) kid on the block	40
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	40
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	38
Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East	36
Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells	36
Artificial intelligence in sickle disease	36
Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization	35
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	35
Not all LGL leukemias are created equal	33
Regulatory T cell niche in the bone marrow, a new player in Haematopoietic stem cell transplantation	33

Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	32
Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management	31
Clinical burden of hemophilia in older adults: Beyond bleeding risk	31
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management	31
Editorial Board	31
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag	29
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	29
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap	29
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	28
Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition	28
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	27
Molecular basis of rare congenital bleeding disorders	27
Metabolic regulation of the bone marrow microenvironment in leukemia	27
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution	27
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML	26
Longitudinal clinical manifestations of Fanconi anemia: A systematized review	26
Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies	25
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	24
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option	24
Targeting cereblon in hematologic malignancies	24
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	23
Knowing the unknowns in high risk multiple myeloma	23
Health related quality of life in children with sickle cell disease: A systematic review and meta-analysis	22
Disparity in hematological malignancies: From patients to health care professionals	21
Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients	21
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	21
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)	21
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	20
The fear for adverse bleeding and cardiovascular events in hemophilia patients using (non-)selective non-steroidal anti-inflammatory drugs: A systematic review reporting on safety	20
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies	20
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	19
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	19
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	19
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	18
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	18
Aiming for the cure in myeloma: Putting our best foot forward	18
Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults	18
Innovations in red blood cell preservation	18
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	18
Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies	17
Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A	17
Autoantibodies in immunodeficiency syndromes: The Janus faces of immune dysregulation	17
Editorial Board	17
Editorial Board	16
Smoldering multiple myeloma – Past, present, and future	16
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism	16
Advances in the management of TTP	15
Chasing leukemia differentiation through induction therapy, relapse and transplantation	15
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink	15
Allogeneic hematopoietic stem cell transplant for sickle cell disease: The why, who, and what	15

Brain-derived neurotrophic factor in hematological malignancies: From detrimental to potentially beneficial